What Are Longevity Labs? Tests, Evidence, and What to Watch For

A longevity lab may mean a clinic, testing company, or research program focused on biomarkers linked to healthy aging. Useful longevity work starts with prevention, clinical risk factors, and validated tests—not promises to reverse aging or extend lifespan. The strongest claims require human clinical evidence, not only animal, cell, or biomarker data 1.

What does “longevity labs” mean?

Longevity labs is a broad phrase. It can describe blood testing, epigenetic age testing, a wellness clinic, or a formal geroscience research program. In medical research, geroscience studies how aging biology may affect diseases such as cardiovascular disease, cancer, chronic respiratory disease, and diabetes 2.

The useful question is not “Can this lab tell me my true age?” It is “Does this test change a health decision in a safe, evidence-based way?” A review of longevity medicine describes the field as focused on early detection, prevention, and personalized care, with prevention and diagnostics forming the base of the “longevity pyramid” 1.

• A consumer longevity test may measure blood markers, DNA methylation, fitness, or sleep data.
• A clinic may combine labs with lifestyle coaching, medications, peptides, or hormone care.
• A research lab may study aging biology using human trials, animal models, or cell systems.
• A credible program should explain what is proven, what is experimental, and what is only a hypothesis.

What is a longevity lab supposed to measure?

A good longevity evaluation should first measure health risks that are already tied to disease, function, and survival. Experimental aging markers may add context, but they should not replace standard care. One lab result rarely predicts a person’s future by itself.

Standard clinical risk markers versus experimental aging biomarkers

Standard clinical risk markers include blood pressure, blood glucose, A1C, lipids, kidney function, liver enzymes, body composition, medication history, tobacco exposure, and family history. These markers are used because they connect to real clinical outcomes, such as cardiovascular disease, diabetes, kidney disease, and all-cause mortality risk 7.

Experimental biomarkers of aging include epigenetic clocks, inflammatory signatures, immune markers, proteomic patterns, metabolomic scores, and cellular aging markers. Some DNA methylation clocks have been linked with healthspan and lifespan in observational research, but that does not mean changing the clock score proves longer life 8.

Healthspan, function, and disease risk are different from lifespan

Healthspan means the years lived with good function and lower disease burden. Lifespan means total years lived. Longevity research often studies frailty, physical disability, functional independence, disease risk, and all-cause mortality because each endpoint answers a different question 2.

For example, a test that tracks inflammation may relate to chronic disease risk, but it does not directly prove that a person will live longer. A trial that shows fewer heart attacks or less physical disability is more clinically meaningful than a biomarker-only change 5.

Why one lab result rarely predicts longevity by itself

Aging is not controlled by one number. Genes, blood pressure, glucose, sleep, strength, mobility, nutrition, medications, mental health, infections, cancer screening, and access to care all matter. That is why credible longevity programs use patterns over time, not a single “biological age” score 1.

Are longevity labs legitimate?

Some are serious medical or research programs. Others are mainly marketing. A legitimate longevity lab should be clear about clinician oversight, test limits, evidence level, privacy, cost, and whether it is selling testing, treatment, research participation, or all three.

Signs of a credible medical or research program

• A licensed clinician reviews medical history, medications, risks, and goals before treatment decisions.
• The program explains whether evidence is from human randomized trials, human observational studies, animal studies, or cell studies.
• Clinical claims are tied to accepted endpoints, such as disease events, function, safety, or quality of life.
• Research studies list informed consent, human subjects protection, data safety monitoring, and Good Clinical Practice safeguards 3.
• The program has clear policies for privacy, follow-up, adverse events, and when to involve a primary care clinician 4.

Red flags: age-reversal guarantees, unsupported lifespan claims, and unclear clinician oversight

Be careful with any program that promises age reversal, guaranteed lifespan extension, disease prevention from unapproved therapies, or “detox” claims without measurable clinical endpoints. FDA notes that geroscience drug development needs a defined indication, intended population, dose plan, proof of concept, and safety information before broad clinical claims can be made 2.

Another red flag is unclear sourcing. A licensed provider and a state-licensed pharmacy are different from no-prescription “research chemical” websites. If a program involves medication, peptide therapy, or hormone care, medical evaluation and follow-up matter.

How to check whether a clinical trial is properly registered and monitored

For a research study, look for registration on ClinicalTrials.gov, a clear sponsor, eligibility criteria, study arms, outcome measures, visit schedule, and safety monitoring plan. ClinicalTrials.gov is a public registry and results database for clinical studies, not a guarantee that a study will benefit you 6.

FDA says clinical trials should protect participant rights, safety, and welfare and should be designed, conducted, analyzed, and reported under federal law and Good Clinical Practice rules 3. NIH guidance also emphasizes human subjects protection, data and safety monitoring, training, privacy, and confidentiality 4.

What evidence supports longevity testing and interventions?

Longevity evidence sits on a ladder. Human clinical evidence is usually strongest for patient decisions, followed by human observational evidence, then animal and cell evidence. Each level can be useful, but each answers a different question.

Human clinical evidence

Human clinical trials are strongest when they measure outcomes patients can feel or avoid: fewer disease events, better function, less disability, fewer serious side effects, or improved quality of life. FDA review of geroscience-related drug programs generally focuses on defined indications, populations, endpoints, and safe dose regimens 2.

Many longevity trials cannot wait decades to measure lifespan directly. That is why they may use intermediate endpoints such as frailty, immune response, glucose control, inflammation, or physical function. Those endpoints still need a clear reason to matter for people 2.

Human observational evidence

Human observational evidence can show that a biomarker is linked with risk. For example, epigenetic clocks based on DNA methylation have been associated with healthspan and lifespan-related outcomes in research cohorts 8. But observational evidence cannot prove that lowering a clock score will extend life.

Animal and cell evidence

Animal and cell studies help researchers test aging pathways before human trials. They may show changes in inflammation, mitochondrial function, cell signaling, wound repair, or survival in a model. The honest limit is that a mouse or cell result is not proof of human lifespan extension 1.

Why preclinical findings should not be treated as proof in people

Preclinical work can be promising and still fail in people because humans have different biology, health histories, medications, diets, and exposure patterns. This is why Chia uses careful language for longevity-related therapies: studied for, may support, or being investigated—not “reverses aging” or “extends lifespan.”

How does FDA view geroscience and longevity drug research?

FDA does not approve a drug just because it changes a biomarker of aging. For geroscience drug research, sponsors usually need a defined indication, a clear study population, safety data, and endpoints that can support a clinical claim 2.

Why aging-related drug claims need clear indications and endpoints

FDA notes that development or repurposing of drugs for geroscience-related programs will generally require review of an Investigational New Drug application unless an exception applies 2. Sponsors are expected to define the context of use, intended population, proof of concept, and safe dosing regimen 2.

Biomarkers versus validated surrogate endpoints

A biomarker is a measurable sign of a biological process. A surrogate endpoint is stronger: it is used in a trial as a substitute for a clinical outcome. FDA’s biomarker qualification program explains that a biomarker must be qualified for a specific context of use before it can be relied on in drug development decisions 5.

That distinction matters for longevity labs. A biological age score may be interesting, but it is not the same as a validated surrogate endpoint for lifespan, disability, cancer, cardiovascular disease, or mortality.

Why safety, eligibility, and monitoring matter

Even low-risk tests can lead to anxiety, false reassurance, unnecessary spending, or treatment choices that do not fit a person’s health history. If a program adds medications, peptides, hormones, or injections, safety review becomes more important. FDA and NIH both emphasize participant safety, monitoring, and ethical conduct in clinical research 3 4.

What labs or markers are commonly discussed in longevity medicine?

Longevity medicine often combines standard medical markers with newer aging tools. Cardiometabolic markers are usually the practical starting point because they connect to common causes of illness and death.

Cardiometabolic risk markers

• Blood pressure and resting heart rate
• A1C, fasting glucose, fasting insulin, and diabetes risk
• LDL cholesterol, HDL cholesterol, triglycerides, and sometimes ApoB or lipoprotein(a)
• Kidney function, liver enzymes, waist size, weight trend, and body composition
• Cardiorespiratory fitness, strength, activity level, and sleep quality

These markers matter because cardiovascular disease, cancer, chronic respiratory disease, and diabetes are major drivers of illness and death in adults 7. A longevity program that ignores these basics in favor of exotic testing is missing the foundation.

Inflammation and immune-related markers

Common inflammation markers include high-sensitivity C-reactive protein and sometimes immune-cell counts or cytokine panels. These can be useful in the right context, but they are nonspecific. Infection, poor sleep, autoimmune disease, obesity, smoking, and recent exercise can all affect results.

Hormones, nutrition, and functional measures

Hormones, vitamin status, iron studies, thyroid markers, and nutrition markers may be relevant when symptoms, age, sex, medications, or medical history make them appropriate. Functional measures—grip strength, walking speed, balance, muscle mass, aerobic capacity, and frailty—often say more about healthspan than a single blood test 1.

Epigenetic clocks and other emerging tools

Epigenetic clocks use DNA methylation patterns to estimate biological aging signals. Horvath’s multi-tissue DNA methylation clock helped launch this field in human tissue research 9. Later work linked epigenetic biomarker scores with healthspan and lifespan-related outcomes in observational cohorts 8.

These tools are not useless, but they are easy to overread. A clock result should not be treated as a diagnosis, a life expectancy estimate, or proof that a treatment works.

How do longevity labs connect to treatment at Chia?

Chia is not a standalone longevity lab. We do not sell direct-to-consumer lab panels, biological age tests, or guaranteed age-reversal programs. At Chia, our role is clinician-reviewed telehealth for eligible patients interested in certain compounded longevity-related treatments.

Chia’s longevity-related options

Chia offers NAD+ (nicotinamide adenine dinucleotide) as an injection from $179/mo or nasal spray from $119/mo; glutathione as an injection or nasal spray from $179/mo; sermorelin (sermorelin acetate, a peptide growth hormone-releasing hormone analog) as an injection, nasal spray, or tablets from $179/mo; and GHK-Cu (copper tripeptide-1/copper peptide complex) as a cream from $159/mo.

We also offer the Foundation Longevity protocol, which includes sermorelin injection, NAD+ injection, and glutathione injection, with plans currently starting at $399/mo. The goal is provider-guided support for selected health goals, not a promise of lifespan extension.

What Chia does not offer

Chia does not offer standalone longevity lab testing, biological age testing, direct lab interpretation as a separate service, or guaranteed age-reversal programs. If lab testing is needed for your broader medical care, that should be handled through an appropriate clinician relationship.

How online clinician review, eligibility, and 503A compounding work

Treatment at Chia starts with a short online health questionnaire. A licensed US provider reviews your information and prescribes only when clinically appropriate. If prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door.

Dosing is provider-guided and adjusted over time when appropriate. Patients can message their care team through the patient portal between visits. A prescription is never guaranteed.

How should patients compare a longevity lab, clinic, or telehealth option?

Compare the purpose before you compare the price. Consumer testing, research trials, and clinician-guided treatment solve different problems. A good choice depends on whether you want information, supervised care, or research participation.

Questions to ask before paying for testing or treatment

1. 1What decision will this test change?
2. 2Is the evidence human clinical, human observational, animal, or cell evidence?
3. 3Does the program make lifespan or age-reversal claims?
4. 4Who reviews the results, and what are their credentials?
5. 5How are abnormal results handled?
6. 6What are the risks, side effects, and reasons I may not be eligible?
7. 7If medication is involved, is there a licensed provider and a state-licensed pharmacy?
8. 8What follow-up is included after the first visit?

When to involve your primary care clinician

Involve your primary care clinician if you have abnormal labs, new symptoms, chronic disease, cancer history, pregnancy, complex medications, hormone concerns, or a major change in weight, sleep, mood, or exercise tolerance. Longevity care should add to primary care, not replace it.

FAQ

Keep reading

Longevity

What Is Longevity Medicine? A Patient Guide to Healthspan, Testing, and Treatments

Longevity

What Is Longevity Health? A Patient Guide to Healthspan, Evidence, and Treatment Options

Longevity

Wisconsin Institute for Healthy Aging: What It Is and How It Fits Into Healthy Aging